Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -45.20% is in line with its 5-year average of -47.01%, around the middle of its 5-year range (-78.03%–-29.81%).
20.08% above its 12-month average of -56.55%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.55%.
RETURN ON ASSETS (ROA)
-45.20%
RETURN ON ASSETS (ROA) AVG TTM
-56.55%
RETURN ON ASSETS (ROA) AVG 3Y
-55.28%
RETURN ON ASSETS (ROA) AVG 5Y
-47.01%
RETURN ON ASSETS (ROA) AVG 10Y
-42.40%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+20.08%
CURRENT VS 3Y AVG
+18.23%
CURRENT VS 5Y AVG
+3.85%
CURRENT VS 10Y AVG
-6.61%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 500 covered companies
CURRENT VS SECTOR MEDIAN
-68.03%
vs the sector median at left
Cogent Biosciences, Inc.
Market Cap
$5.27B
Return on Assets (ROA)
-45.20%
TTM Avg
-56.55%
3Y Avg
-55.28%
5Y Avg
-47.01%
Market Cap
$5.35B
Return on Assets (ROA)
15.41%
TTM Avg
17.55%
3Y Avg
14.67%
5Y Avg
15.71%
Market Cap
$5.20B
Return on Assets (ROA)
5.08%
TTM Avg
4.88%
3Y Avg
4.58%
5Y Avg
3.44%
Market Cap
$5.20B
Return on Assets (ROA)
-78.04%
TTM Avg
-72.67%
3Y Avg
-59.05%
5Y Avg
-50.29%
Market Cap
$5.11B
Return on Assets (ROA)
-66.02%
TTM Avg
-31.80%
3Y Avg
-35.60%
5Y Avg
-41.38%
Market Cap
$5.53B
Return on Assets (ROA)
-17.02%
TTM Avg
-21.01%
3Y Avg
-19.47%
5Y Avg
-13.88%
Market Cap
$5.02B
Return on Assets (ROA)
4.59%
TTM Avg
-6.29%
3Y Avg
-18.57%
5Y Avg
-18.57%
Market Cap
$4.92B
Return on Assets (ROA)
-2.47%
TTM Avg
-26.65%
3Y Avg
-27.96%
5Y Avg
-27.52%
Market Cap
$4.81B
Return on Assets (ROA)
-31.79%
TTM Avg
-38.86%
3Y Avg
-47.00%
5Y Avg
-47.76%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | $5.27B | -45.20% | -56.55% | -55.28% | -47.01% |
| Doximity, Inc. (DOCS)vs › | $5.35B | 15.41% | 17.55% | 14.67% | 15.71% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.20B | 5.08% | 4.88% | 4.58% | 3.44% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.20B | -78.04% | -72.67% | -59.05% | -50.29% |
| Erasca, Inc. (ERAS)vs › | $5.11B | -66.02% | -31.80% | -35.60% | -41.38% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.53B | -17.02% | -21.01% | -19.47% | -13.88% |
| BillionToOne, Inc. (BLLN)vs › | $5.02B | 4.59% | -6.29% | -18.57% | -18.57% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.92B | -2.47% | -26.65% | -27.96% | -27.52% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.81B | -31.79% | -38.86% | -47.00% | -47.76% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.78B | -9.97% | -20.59% | -24.65% | -22.36% |
ROA
-45.2%
ROE
-70.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -35.08% |
| 2024-12-31 | -78.03% |
| 2023-12-31 | -61.39% |
| 2022-12-31 | -46.62% |
| 2021-12-31 | -31.14% |
| 2020-12-31 | -29.81% |
| 2019-12-31 | -61.25% |
| 2018-12-31 | -40.19% |
| 2017-12-31 | -51.90% |
| 2016-12-31 | -23.99% |
| 2015-12-31 | -6.96% |
